Lepu Biopharma Co (HKSE:02157) ROCE % : -25.53% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Lepu Biopharma Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lepu Biopharma Co's annualized ROCE % for the quarter that ended in Jun. 2024 was -25.53%.

Lepu Biopharma Co ROCE % Historical Data

The historical data trend for Lepu Biopharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lepu Biopharma Co ROCE % Chart

Lepu Biopharma Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-149.58

-45.30

-58.48

-41.11

-0.97

Lepu Biopharma Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial				-38.77	-36.87	-16.64	15.87	-25.53

Lepu Biopharma Co ROCE % Calculation

Lepu Biopharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-17.089	/	( ( (2824.364 - 942.268)	+	(2607.904 - 983.921) )	/ 2 )
	=	-17.089	/	( (1882.096	+	1623.983)	/ 2 )
	=	-17.089	/	1753.0395
	=	-0.97 %

Lepu Biopharma Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-407.222	/	( ( (2607.904 - 983.921)	+	(2627.852 - 1061.268) )	/ 2 )
	=	-407.222	/	( ( 1623.983	+	1566.584 )	/ 2 )
	=	-407.222	/	1595.2835
	=	-25.53 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Lepu Biopharma Co (HKSE:02157) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lepu Biopharma Co ROCE % Related Terms

Thank you for viewing the detailed overview of Lepu Biopharma Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lepu Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lepu Biopharma Co Ltd (HKSE:02157) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 651, Lianheng Road, Minhang District, Shanghai, CHN, 201612

Website

https://www.lepubiopharma.com

Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in the PRC. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain.

Executives

Pu Zhongjie	2201 Interest of corporation controlled by you
Hu Chaohong	2201 Interest of corporation controlled by you
Pu Jue	2201 Interest of corporation controlled by you
Hao Chunmei	2202 Interest of your spouse
Su Rongyu	2101 Beneficial owner
Miracogen Inc.	2201 Interest of corporation controlled by you
Miracogen Limited	2101 Beneficial owner
Cereblue Limited	2201 Interest of corporation controlled by you
Bei Jing Hou De Yi Min Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Hou De Yi Min Xin Xi Ke Ji You Xian Gong Si	2101 Beneficial owner
Le Pu Bei Jing Yi Liao Qi Xie Gu Fen You Xian Gong Si	2101 Beneficial owner
Lv Yuan Shang Hai Ke Ji You Xian Gong Si	2101 Beneficial owner

Lepu Biopharma Co Headlines

No Headlines